View Item 

Show simple item record

Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement
dc.contributor.authorBratslavsky, Gennady
dc.contributor.authorMendhiratta, Neil
dc.contributor.authorDaneshvar, Michael
dc.contributor.authorBrugarolas, James
dc.contributor.authorBall, Mark W.
dc.contributor.authorMetwalli, Adam
dc.contributor.authorNathanson, Katherine L.
dc.contributor.authorPierorazio, Phillip M.
dc.contributor.authorBoris, Ronald S.
dc.contributor.authorSinger, Eric A.
dc.contributor.authorCarlo, Maria I.
dc.contributor.authorDaly, Mary B.
dc.contributor.authorHenske, Elizabeth P.
dc.contributor.authorHyatt, Colette
dc.contributor.authorMiddleton, Lindsay
dc.contributor.authorMorris, Gloria
dc.contributor.authorJeong, Anhyo
dc.contributor.authorNarayan, Vivek
dc.contributor.authorRathmell, W. Kimryn
dc.contributor.authorVaishampayan, Ulka
dc.contributor.authorLee, Bruce H.
dc.contributor.authorBattle, Dena
dc.contributor.authorHall, Michael J.
dc.contributor.authorHafez, Khaled
dc.contributor.authorJewett, Michael A. S.
dc.contributor.authorKaramboulas, Christina
dc.contributor.authorPal, Sumanta K.
dc.contributor.authorHakimi, A. Ari
dc.contributor.authorKutikov, Alexander
dc.contributor.authorIliopoulos, Othon
dc.contributor.authorLinehan, W. Marston
dc.contributor.authorJonasch, Eric
dc.contributor.authorSrinivasan, Ramaprasad
dc.contributor.authorShuch, Brian
dc.date.accessioned2021-11-02T00:47:06Z
dc.date.available2022-12-01 20:47:05en
dc.date.available2021-11-02T00:47:06Z
dc.date.issued2021-11-01
dc.identifier.citationBratslavsky, Gennady; Mendhiratta, Neil; Daneshvar, Michael; Brugarolas, James; Ball, Mark W.; Metwalli, Adam; Nathanson, Katherine L.; Pierorazio, Phillip M.; Boris, Ronald S.; Singer, Eric A.; Carlo, Maria I.; Daly, Mary B.; Henske, Elizabeth P.; Hyatt, Colette; Middleton, Lindsay; Morris, Gloria; Jeong, Anhyo; Narayan, Vivek; Rathmell, W. Kimryn; Vaishampayan, Ulka; Lee, Bruce H.; Battle, Dena; Hall, Michael J.; Hafez, Khaled; Jewett, Michael A. S.; Karamboulas, Christina; Pal, Sumanta K.; Hakimi, A. Ari; Kutikov, Alexander; Iliopoulos, Othon; Linehan, W. Marston; Jonasch, Eric; Srinivasan, Ramaprasad; Shuch, Brian (2021). "Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement." Cancer (21): 3957-3966.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/170869
dc.publisherWiley Periodicals, Inc.
dc.publisherNCCN
dc.subject.otherrenal cell carcinoma
dc.subject.othergenetic risk assessment
dc.subject.othergenetic testing
dc.subject.othergermline mutations
dc.subject.otherhereditary kidney cancer
dc.subject.otherrecommendations
dc.subject.otherclinical consensus
dc.titleGenetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/170869/1/cncr33679_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/170869/2/cncr33679.pdf
dc.identifier.doi10.1002/cncr.33679
dc.identifier.sourceCancer
dc.identifier.citedreferenceSiegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69: 7 ‐ 34. doi: 10.3322/caac.21551
dc.identifier.citedreferenceIsla D, de Castro J, Garcia‐Campelo R, et al. Treatment options beyond immunotherapy in patients with wild‐type lung adenocarcinoma: a Delphi consensus. Clin Transl Oncol. 2020; 22: 759 ‐ 771. doi: 10.1007/s12094‐019‐02191‐y
dc.identifier.citedreferenceLinehan WM, Ricketts CJ. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. Nat Rev Urol. 2019; 16: 539 ‐ 552. doi: 10.1038/s41585‐019‐0211‐5
dc.identifier.citedreferenceCarlo MI, Mukherjee S, Mandelker D, et al. Prevalence of germline mutations in cancer susceptibility genes in patients with advanced renal cell carcinoma. JAMA Oncol. 2018; 4: 1228 ‐ 1235. doi: 10.1001/jamaoncol.2018.1986
dc.identifier.citedreferenceHuang KL, Mashl RJ, Wu Y, et al. Pathogenic germline variants in 10,389 adult cancers. Cell. 2018; 173: 355 ‐ 370.e14. doi: 10.1016/j.cell.2018.03.039
dc.identifier.citedreferenceShuch B, Vourganti S, Ricketts CJ, et al. Defining early‐onset kidney cancer: implications for germline and somatic mutation testing and clinical management genetic counseling. J Clin Oncol. 2014; 32: 431 ‐ 437.
dc.identifier.citedreferenceAdeniran AJ, Shuch B, Humphrey PA. Hereditary renal cell carcinoma syndromes. Am J Surg Pathol. 2015; 39: e1 ‐ e18. doi: 10.1097/PAS.0000000000000562
dc.identifier.citedreferenceAluwini SS, Mehra N, Lolkema MP, et al. Oligometastatic prostate cancer: results of a Dutch multidisciplinary consensus meeting. Eur Urol Oncol. 2020; 3: 231 ‐ 238. doi: 10.1016/j.euo.2019.07.010
dc.identifier.citedreferenceGiri VN, Knudsen KE, Kelly WK, et al. Implementation of germline testing for prostate cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020; 38: 2798 ‐ 2811. doi: 10.1200/JCO.20.00046
dc.identifier.citedreferenceGiri VN, Knudsen KE, Kelly WK, et al. Role of genetic testing for inherited prostate cancer risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018; 36: 414 ‐ 424. doi: 10.1200/JCO.2017.74.1173
dc.identifier.citedreferenceLam TBL, MacLennan S, Willemse PPM, et al. EAU‐EANM‐ESTRO‐ESUR‐SIOG Prostate Cancer Guideline Panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international collaborative study (DETECTIVE Study). Eur Urol. 2019; 76: 790 ‐ 813. doi: 10.1016/j.eururo.2019.09.020
dc.identifier.citedreferenceLapini A, Caffo O, Pappagallo G, et al. Monitoring patients with metastatic hormone‐sensitive and metastatic castration‐resistant prostate cancer: a multidisciplinary consensus document. Cancers (Basel). 2019; 11: 1908.
dc.identifier.citedreferenceHall MJ, Patrick‐Miller LJ, Egleston BL, et al. Use and patient‐reported outcomes of clinical multigene panel testing for cancer susceptibility in the Multicenter Communication of Genetic Test Results by Telephone Study. JCO Precis Oncol. 2018; 2: PO.18.00199. doi: 10.1200/po.18.00199
dc.identifier.citedreferenceCohen SA, Bradbury A, Henderson V, Hoskins K, Bednar E, Arun BK. Genetic counseling and testing in a community setting: quality, access, and efficiency. Am Soc Clin Oncol Educ Book. 2019; 39: e34 ‐ e44. doi: 10.1200/edbk_238937
dc.identifier.citedreferenceHilgart JS, Hayward JA, Coles B, Iredale R. Telegenetics: a systematic review of telemedicine in genetics services. Genet Med. 2012; 14: 765 ‐ 776. doi: 10.1038/gim.2012.40
dc.identifier.citedreferenceHoskovec JM, Bennett RL, Carey ME, et al. Projecting the supply and demand for certified genetic counselors: a workforce study. J Genet Couns. 2018; 27: 16 ‐ 20. doi: 10.1007/s10897‐017‐0158‐8
dc.identifier.citedreferenceGreen BB, Coronado GD, Devoe JE, Allison J. Navigating the murky waters of colorectal cancer screening and health reform. Am J Public Health. 2014; 104: 982 ‐ 986. doi: 10.2105/AJPH.2014.301877
dc.identifier.citedreferenceRobson ME, Bradbury AR, Arun B, et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2015; 33: 3660 ‐ 3667. doi: 10.1200/JCO.2015.63.0996
dc.identifier.citedreferenceEaston DF, Pharoah PDP, Antoniou AC, et al. Gene‐panel sequencing and the prediction of breast‐cancer risk. N Engl J Med. 2015; 372: 2243 ‐ 2257. doi: 10.1056/NEJMsr1501341
dc.identifier.citedreferenceLynce F, Isaacs C. How far do we go with genetic evaluation? Gene, panel, and tumor testing. Am Soc Clin Oncol Educ Book. 2016; 35: e72 ‐ e78. doi: 10.14694/edbk_160391
dc.identifier.citedreferenceShuch B, Singer EA, Bratslavsky G. The surgical approach to multifocal renal cancers: hereditary syndromes, ipsilateral multifocality, and bilateral tumors. Urol Clin North Am. 2012; 39: 133 ‐ 148. doi: 10.1016/j.ucl.2012.01.006
dc.identifier.citedreferenceHampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med. 2015; 17: 70 ‐ 87. doi: 10.1038/gim.2014.147
dc.identifier.citedreferenceMotzer RJ, Jonasch E, Boyle S, et al. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. J Natl Compr Cancer Netw. 2020; 18: 1160 ‐ 1170. doi: 10.6004/jnccn.2020.0043
dc.identifier.citedreferenceCampbell S, Uzzo RG, Allaf ME, et al. Renal mass and localized renal cancer: AUA guideline. J Urol. 2017; 198: 520 ‐ 529. doi: 10.1016/j.juro.2017.04.100
dc.identifier.citedreferenceLjungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015; 67: 913 ‐ 924. doi: 10.1016/j.eururo.2015.01.005
dc.identifier.citedreferenceBrierley KL, Campfield D, Ducaine W, et al. Errors in delivery of cancer genetics services: implications for practice. Conn Med. 2010; 74: 413 ‐ 423.
dc.identifier.citedreferenceBrierley KL, Blouch E, Cogswell W, et al. Adverse events in cancer genetic testing: medical, ethical, legal, and financial implications. Cancer J. 2012; 18: 303 ‐ 309. doi: 10.1097/PPO.0b013e3182609490
dc.identifier.citedreferenceLaforest F, Mann B, Edwards A, Kirkegaard P. Genetic cancer risk assessment in general practice: systematic review of tools available, clinician attitudes, and patient outcomes. Br J Gen Pract. 2019; 69: e97 ‐ e105. doi: 10.3399/bjgp18X700265
dc.identifier.citedreferenceShuch B, Zhang J. Genetic predisposition to renal cell carcinoma: implications for counseling, testing, screening, and management. J Clin Oncol. 2018; 36: 3560 ‐ 3566. doi: 10.1200/JCO.2018.79.2523
dc.identifier.citedreferenceNational Comprehensive Cancer Network (NCCN). NCCN Guidelines and Clinical Resources. NCCN; 2020. https://www.nccn.org/professionals/development.aspx. Accessed May 14, 2020.
dc.identifier.citedreferenceNguyen KA, Syed JS, Espenschied CR, et al. Advances in the diagnosis of hereditary kidney cancer: initial results of a multigene panel test. Cancer. 2017; 123: 4363 ‐ 4371. doi: 10.1002/cncr.30893
dc.identifier.citedreferenceMucci LA, Hjelmborg JB, Harris JR, et al. Familial risk and heritability of cancer among twins in Nordic countries. JAMA. 2016; 315: 68 ‐ 76. doi: 10.1001/jama.2015.17703
dc.identifier.citedreferenceHaas NB, Nathanson KL. Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis. 2014; 21: 81 ‐ 90. doi: 10.1053/j.ackd.2013.10.001
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr33679_am.pdf
Size:
289.3KB
Format:
PDF
View/Open
Name:
cncr33679.pdf
Size:
193.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.